192 filings
Page 5 of 10
6-K
rc0ecwdn tw
23 Jun 21
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the The study’s primary efficacy endpoint, a statistically significant increase in P1NP at 3 months was achieved, as previously reported
8:30am
6-K
otccfsfjj1som1rzxr5
22 Jun 21
At Market Issuance Sales Agreement
5:25pm
6-K
k399i6 af7wbz
17 Jun 21
Entera Bio Receives Foundational Patent for its Oral PTH using its Platform
8:02am
6-K
wfncovunqw9apq56s
20 May 21
Condensed Consolidated Interim Financial Statements
8:02am
6-K
actns
20 May 21
Entera Bio Reports First Quarter 2021 Financial Results and Provides
8:00am
424B5
uaofmit
7 May 21
Prospectus supplement for primary offering
5:05pm
6-K
jlbee6mct6p
20 Apr 21
Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors
8:30am
6-K
aldga5g
15 Apr 21
Entera Appoints Ramesh Ratan As Chief Financial Officer
8:30am
6-K
y7stnau55zuvky1
6 Apr 21
New Data Suggest Entera’s Platform Orally Delivers Human Growth Hormone, Study
8:30am
6-K
66rmych py
18 Mar 21
Entera Bio LTD Announces Operating and Financial Results for the 2020 and Recent Highlights
8:00am
6-K
y52k8dle 73x
11 Mar 21
Entera Bio LTD Announces Positive Topline EB613 Phase 2 Biomarker Data
8:30am
6-K
3tuegox 7gje3ta1qi
3 Mar 21
Current report (foreign)
5:00pm
6-K
2cszfh
25 Feb 21
Entera Bio Announces Publication of Phase 2 Hypoparathyroidism
8:30am
6-K
049xw5qtoirxk43
8 Feb 21
Current report (foreign)
8:30am
6-K
5fwyuq58rv 6pz
11 Jan 21
Current report (foreign)
9:46am
6-K
iibth
11 Jan 21
Entera Bio Issues Letter to Shareholders
8:30am
6-K
mmn2h9dzb5x301e6lc
10 Dec 20
Current report (foreign)
8:30am
6-K
i8y5xo4 b45ng5ursv
30 Nov 20
Entera Bio Appoints Spiros Jamas As Chief Executive Officer
4:05pm
6-K
ivz6gtsw6hgccqie4q8
19 Nov 20
Condensed Consolidated Interim Financial Statements
8:30am